Abstract
Background Few studies assessed the perinatal death (PD) risk for congenital heart defects (CHDs).
Methods Data were obtained from the Birth Defects Surveillance System in Hunan Province, China, 2016–2020. Perinatal mortality (stillbirths and early neonatal deaths per 1000 fetuses (>=28 weeks)) and 95% confidence intervals (CI) were calculated. Crude odds ratios (ORs) and 95%CI were calculated to estimate the PD risk for CHDs and to examine the association of each maternal characteristic with PD risk for CHDs.
Results 847755 fetuses were registered, including 14459 (1.71%) birth defects (4161 CHDs, 0.49%) and 833296 (98.29%) cases without birth defects. 7445 PDs (6874 stillbirths and 571 early neonatal deaths) were identified, including 976 (13.11%) CHD-related deaths, and 4396 PDs for fetuses without birth defects. 97.50% (936/960) of CHD-related stillbirths were selective termination of pregnancy. The overall perinatal mortality was 0.88% (95%CI: 0.86-0.90). CHDs increased the PD risk (23.46% vs. 0.53%, OR=57.78, 95%CI: 53.47-62.44). Any specific CHD increased the PD risk (OR>1, P<0.05). Perinatal mortality for CHDs was higher in rural than urban areas (OR= 3.40, 95%CI: 2.92-3.95). And perinatal mortalities for CHDs were higher in low maternal age (<25 years old), low per-capita annual income (<4000¥), low maternal education, no birth, and premature birth compared to the reference group. (OR>1, P<0.05).
Conclusions CHDs significantly increase the PD risk. Several maternal characteristics were associated with CHD-related PDs. And several mechanisms have been proposed to explain these phenomena. Our results are of immediate value for clinical care and consultation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Medical Ethics Committee of Hunan Provincial Maternal and Child Health Care Hospital approved the study. (NO: 2022-S64).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Complete address: No. 53 Xiangchun Road, Changsha, Hunan Province
Data Availability
All data generated or analyzed during this study are included in this published article.
